A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

144 sites for NCT03336333

del(17)(p10), +1 more biomarker

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

bendamustine, +3 more drugs

chemotherapy, +2 more types

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

388 sites for NCT03937635

del(17)(p10), +3 more biomarkers

Smoldering Plasma Cell Myeloma

daratumumab, +2 more drugs

chemotherapy, +2 more types

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)

14 sites for NCT04571645

ASXL1 Loss, +27 more biomarkers

Acute Myeloid Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

55 sites for NCT02875314

APC Loss, +67 more biomarkers

Central Nervous System Embryonal Neoplasm, +9 more conditions

carboplatin, +9 more drugs

chemotherapy, +1 more type

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

23 sites for NCT01878617

APC Loss, +36 more biomarkers

Intracranial Primitive Neuroectodermal Neoplasm, +1 more condition

cisplatin, +6 more drugs

chemotherapy, +2 more types

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

1 site for NCT04797767

ASXL1 Loss, +23 more biomarkers

Acute Biphenotypic Leukemia, +2 more conditions

cladribine, +4 more drugs

chemotherapy, +1 more type

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

1 site for NCT04990323

ASXL1 Loss, +23 more biomarkers

Acute Myeloid Leukemia, +4 more conditions

ECT-001 expanded cord blood

cellular therapy

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

9 sites for NCT04167618

CDK6 Amplification, +61 more biomarkers

Medulloblastoma, +2 more conditions

lutetium Lu 177-DTPA-omburtamab

immunotherapy, +1 more type

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

22 sites for NCT04232241

ASXL1 Loss, +31 more biomarkers

Acute Lymphoblastic Leukemia, +2 more conditions

allogeneic hematopoietic stem cell transplantation

cellular therapy

Optimizing PTCy Dose and Timing

1 site for NCT03983850

ASXL1 Loss, +49 more biomarkers

Acute Myeloid Leukemia, +12 more conditions

busulfan, +4 more drugs

chemotherapy, +1 more type

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

1 site for NCT04817241

ASXL1 Loss, +24 more biomarkers

Acute Myeloid Leukemia

cytarabine, +3 more drugs

chemotherapy